July 24 Celgene Corp reported a 25
percent increase in quarterly profit, helped by robust sales of
its flagship cancer drug, Revlimid.
The U.S. biotechnology company's net profit rose to $597.8
million, or 72 cents per share, in the second quarter ended June
30, from $478.1 million, or 56 cents per share, a year earlier.
Excluding special items, it earned 90 cents per share.
Total revenue rose 17 percent to $1.87 billion.
Sales of multiple myeloma treatment Revlimid rose 15 percent
to $1.21 billion.
(Reporting by Anand Basu in Bangalore; Editing by Maju Samuel)